UK‐PDRG 2001.

Methods	G: random number tables C: central allocation Patients/doctors/assessors all unblinded Intention‐to‐treat
Participants	UK 520 randomised 271 to selegiline; 249 to control Incl: untreated idiopathic PD with incapacity requiring dopaminergic treatment Excl: dementia, previously failed to respond to dopaminergic drugs Baseline mean WRS: selegiline 11; control 11
Interventions	Treatment: selegiline 5 mg twice a day Control: no selegiline Both groups received levodopa Mean mortality FU: 9.2 years
Outcomes	Deaths Mean levodopa dose Motor fluctuations Dyskinesias Withdrawals due to side‐effects Total withdrawals
Notes	Mean FU: 9.2 yrs (11.4 yrs for mortality) No washout
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "random number tables"
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was carried out by an independent coordinator" Quote: "the investigators telephoned the coordinator for the treatment code, which was subsequently confirmed in writing."
Blinding (performance bias and detection bias) Doctors, All outcomes	High risk	Quote: “An open, randomised trial” Comment: Not blinded. Unlikely to bias mortality data but may influence other more subjective outcomes.
Blinding (performance bias and detection bias) Patients, All outcomes	High risk
Blinding (performance bias and detection bias) Outcome assessors, All outcomes	High risk
Incomplete outcome data (attrition bias) Mortality	Low risk	Rx: 271 randomised, 267 analysed (four lost to mortality FU) C: 249 randomised, 243 analysed (six lost to mortality FU)
Incomplete outcome data (attrition bias) Parkinsonian impairment & disability	Low risk	Outcome not included in this review (assessed using Webster rating scale not UPDRS)
Incomplete outcome data (attrition bias) Participants requiring levodopa	Low risk	Outcome not assessed
Incomplete outcome data (attrition bias) Motor fluctuations & dyskinesias	Low risk	Rx: 271 randomised, 268 analysed (as rate per 1,000 person‐yrs FU). C: 249 randomised, 240 analysed (as rate per 1,000 person‐yrs FU)
Selective reporting (reporting bias)	Unclear risk	No protocol available.
Other bias	Unclear risk	Different mean durations of FU: slightly longer in selegiline arm (3.8 vs 3.4 yrs). Quote: "sponsorship from Britannia Pharmaceuticals and Sandoz Products"